摘要
Background and Aims:Few previous studies have reported on a combination response(hepatitis B virus(HBV)DNA undetected,alanine aminotransferase normalization and hepatitis B e antigen(HBeAg)seroconversion)following nucleos(t)ide analogue(NAs)long-term therapy in patients with chronic hepatitis B(CHB).This study aimed to investigate the combination response on long-term NAs therapy in patients with HBeAg-positive CHB and to determine whether prolonged therapy is beneficial for combination response,particularly in optimal patients(baseline alanine aminotransferase level≥5 upper limit of normal and HBV DNA level<10^(9) copies/mL).Methods:In total,280 HBeAg-positive CHB patients were enrolled in this study.Among them,190 were treated with entecavir and 90 were treated with telbivudine.Results:The cumulative rates of combination response in the total number of patients were 8.6%at 1 year,13.2%at 2 years,19.1%at 3 years,24.2%at 4 years and 26.0%at 5 years.In optimal patients,the cumulative rate of combination response was significantly higher than that in the non-optimal patients at 3 years(p=0.043);the trend of the cumulative rate was not strong at the later time.Interestingly,in optimal patients,combination response mainly occurred in the first 3 years.Multivariate analysis identified HBeAg/anti-HBe seroconversion at 1 year as the only factor for combination response in optimal patients(hazard ratio:16.321;p=0.000).During the 3 years,the proportion with aspartate aminotransaminase to platelet ratio index≤0.5 increased from 15.6%at baseline to 71.3%at year 3.Conclusions:Upgrading the rate of combination response is limited by prolonging the treatment duration of NAs from 3 years to 5 years in HBeAg-positive CHB patients;a new switch treatment strategy modification should be considered,particularly in optimal patients.
基金
The authors thank the patients,investigators and study centers for their participation
This study was supported in part by grants from the National Natural Science Foundation of China(Nos.30930082,81171561,30972584)
the National Science and Technology Major Project of China(Nos.2008ZX10002-006,2012ZX10002007001,2017ZX10202203-007,2017ZX10202203-008)
